{"nctId":"NCT00313209","briefTitle":"Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)","startDateStruct":{"date":"2006-04"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":933,"armGroups":[{"label":"Roflumilast","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Roflumilast"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Roflumilast","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* History of COPD for at least 12 months prior to baseline visit\n* FEV1/FVC ratio (post-bronchodilator) ≤ 70%\n* FEV1 (post-bronchodilator) between ≥ 40% and ≤ 70% of predicted\n\nMain Exclusion Criteria:\n\n* COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to baseline visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)","description":"Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \\[L\\]","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":"9"},{"groupId":"OG001","value":"-10","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Post-bronchodilator FEV1","description":"Mean change from baseline during the treatment period in post-bronchodilator FEV1 \\[L\\]","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":"9"},{"groupId":"OG001","value":"8","spread":"9"}]}]}]},{"type":"SECONDARY","title":"COPD Exacerbation Rate (Mild, Moderate or Severe)","description":"Mean rate of COPD exacerbations requiring rescue medication of 3 or more puffs/day on at least 2 consecutive days (=mild COPD exacerbations), or requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \\[ATS / ERS 2005\\].","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Transition Dyspnea Index (TDI) Focal Score","description":"The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.1"},{"groupId":"OG001","value":"1.1","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Shortness of Breath Questionnaire (SOBQ) Total Score","description":"Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is \"not at all breathless\" and five is \"maximally breathless or too breathless to do the activity\".","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.7"},{"groupId":"OG001","value":"-1.1","spread":"0.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":466},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Diarrhoea","Weight decreased","Nausea"]}}}